Drugs / LY2140023
LY2140023
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT03321617 | Apr 2018 → Mar 2020 | — | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT02919774 | Oct 2016 → Apr 2018 | — | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT02234687 | Sep 2014 → Feb 2016 | post-traumatic stress disorder | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1 | NCT01659177 | Aug → Sep 2012 | — | Denovo Biopharma LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT01637142 | Jul 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01609218 | Jun → Sep 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01606436 | Jun → Aug 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01591330 | Apr → Jun 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01524237 | Apr 2012 → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01475136 | Nov 2011 → Dec 2012 | liver disorder | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01440478 | Sep → Oct 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01354353 | May 2011 → Mar 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT01125358 | May 2010 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01086748 | Mar 2010 → May 2012 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01052103 | Jan 2010 → Jun 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00845026 | Mar 2009 → May 2010 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00520923 | Sep 2007 → Oct 2008 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00149292 | Aug 2005 → Jul 2006 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01129674 | Jun 2010 → Oct 2012 | schizophrenia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01487083 | Dec 2011 → Oct 2012 | schizophrenia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01452919 | Nov 2011 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 3 | NCT01328093 | Apr 2011 → Oct 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01307800 | Mar 2011 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2140023 | “The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in...” NCT02919774 ↗18“160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.” NCT00520923 ↗ |
| Known as | LY2140023 Monohydrate | “Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors.” PMID 25539791 ↗ Dec 20141“Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.” PMID 24772351 ↗ Mar 2014 |
| Known as | POMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919774 ↗ |
| Known as | pomaglumetad | “existing clinical trial database of pomaglumetad methionil (pomaglumetad) to demonstrate treatment response in targeted patient populations.” PMID 25890643 ↗ Mar 2015 |
| Known as | Pomaglumetad Methionil | “The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in...” NCT02919774 ↗6“Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors.” PMID 25539791 ↗ Dec 2014 “Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.” PMID 24772351 ↗ Mar 2014 “existing clinical trial database of pomaglumetad methionil (pomaglumetad) to demonstrate treatment response in targeted patient populations.” PMID 25890643 ↗ Mar 2015 |
| Action | Activate | “a receptor agonist that modulates the glutamatergic activity” NCT00149292 ↗ |
| Route | Oral | “taken orally as 80mg twice daily” NCT00520923 ↗ |